8-K: Inhibrx Biosciences Secures $150 Million Loan Facility from Oxford Finance

Inhibrx Biosciences has entered into a loan agreement with Oxford Finance for a term loan facility of up to $150 million to bolster strategic flexibility.

Summary

• Inhibrx Biosciences secured a loan and security agreement with Oxford Finance for a term loan facility of up to $150 million.
• The initial funding was $100 million on January 13, 2025, with an additional $50 million available at Oxford Finance's discretion.
• The loan matures on January 1, 2030, and bears interest at 5.61% plus the greater of 1-Month Term SOFR or 4.34%.
• Interest-only payments are required through February 1, 2028, followed by 23 months of equal principal and interest payments.
• A final payment of 9.0% of the total repaid principal is due upon maturity, acceleration, or prepayment.
• Prepayment is allowed with fees ranging from 2.0% to 5.0%, depending on the timing.
• Inhibrx issued warrants to Oxford Finance to purchase 140,741 shares of common stock at $14.21 per share with the initial tranche.
• Additional warrants will be issued with any further funding, equal to 2.0% of the additional funding divided by the lower of the average or closing price of the common stock.
• The loan agreement includes covenants that restrict the ability of the company to incur debt, grant liens, engage in mergers, make investments, enter into transactions with affiliates, pay dividends, and sell assets.
• The company must maintain a minimum liquidity threshold, which may increase based on pipeline development changes.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Securing a significant loan facility is generally a positive development, providing financial resources for ongoing operations and clinical trials. However, the debt also introduces financial obligations and potential risks.

Positives

• The $150 million loan facility provides Inhibrx with strategic financial flexibility.
• The interest-only period until March 2028 allows Inhibrx to focus on clinical development.
• The ability to draw down an additional $50 million provides further financial runway if needed.
• The loan is secured by the company's assets, indicating confidence from the lender in Inhibrx's prospects.

Negatives

• The loan agreement includes restrictive covenants that limit Inhibrx's operational flexibility.
• The minimum liquidity threshold requirement could constrain Inhibrx's ability to deploy capital.
• The warrants issued to Oxford Finance dilute existing shareholders' equity.
• The loan is secured by substantially all of Inhibrx's assets, increasing the risk in case of default.

Risks

• Failure to comply with the loan covenants could trigger an event of default and acceleration of the debt.
• Inability to maintain the minimum liquidity threshold could limit Inhibrx's operational flexibility.
• Uncertainty regarding the availability of the additional $50 million, as it is subject to the lender's discretion.
• Clinical trial results may not be positive, impacting the company's ability to generate revenue and repay the loan.
• Delisting from The Nasdaq Global Market would trigger an event of default.

Future Outlook

Inhibrx anticipates that the loan facility will provide strategic flexibility following data readouts expected later in the year for its INBRX-109 and INBRX-106 programs.

Management Comments

• Kelly Deck, CFO of Inhibrx, stated that the loan enables strategic flexibility post data readouts for the INBRX-109 and INBRX-106 programs.
• Christopher Herr, Senior Managing Director at Oxford, expressed pride in furthering their partnership with Inhibrx and supporting the advancement of their pipeline.

Industry Context

This financing is typical for clinical-stage biopharmaceutical companies seeking to fund ongoing research and development activities. Venture debt from firms like Oxford Finance is a common source of capital for companies that have promising clinical assets but are not yet generating revenue.

Comparison to Industry Standards

• Similar biotech companies, such as BioCryst Pharmaceuticals and Madrigal Pharmaceuticals, have utilized debt financing to advance their clinical programs.
• The interest rate and warrant coverage are within the typical range for venture debt in the biopharmaceutical industry, reflecting the risk profile of the company and the stage of its clinical development programs.
• The covenants included in the loan agreement are standard for this type of financing, designed to protect the lender's investment while allowing the company to operate its business.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of warrants.
• Employees benefit from the company's increased financial stability.
• Customers (patients) may benefit from the advancement of clinical programs.
• Suppliers and creditors gain assurance from the company's improved financial position.

Next Steps

• Inhibrx will continue to advance its INBRX-109 and INBRX-106 programs.
• Inhibrx will monitor its liquidity position to ensure compliance with the loan covenants.
• Inhibrx may draw down the additional $50 million, subject to the lender's discretion.
• Inhibrx will prepare for key data readouts expected in 2025.

Key Dates